Safety and effectiveness of ticarcillin plus clavulanic acid in the treatment of community-acquired acute pyelonephritis in adult women.
An open study was conducted to evaluate the safety and effectiveness of ticarcillin plus clavulanic acid in the treatment of 18 adult women with community-acquired Escherichia coli acute pyelonephritis. Eleven of the 18 patients had a history of urinary tract infections, primarily acute pyelonephritis. Six patients had blood culture results positive for E. coli in addition to positive urine culture results. Ticarcillin plus clavulanic acid was administered as the 3.2 g formulation to 11 patients and as the 3.1 g formulation to the other seven. The mean duration of treatment was 9.2 days. Five of the 18 (28 percent) patients had clinical and bacteriologic cures; there were 11 (69 percent) relapses or reinfections and two (11 percent) clinical failures. Adverse reactions (all reversible) were reported in 11 (61 percent) patients, the most frequent of which was phlebitis. These results should prompt further investigation into the treatment of acute pyelonephritis with ticarcillin plus clavulanic acid versus other antibiotics.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D004341:Drug Evaluation; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010406:Penicillins / Q000008:administration & dosage*; D010878:Piperacillin / Q000627:therapeutic use; D011704:Pyelonephritis / Q000188:drug therapy*; D013982:Ticarcillin / Q000008:administration & dosage* / Q000009:adverse effects
D002969:Clavulanic Acids; D004338:Drug Combinations; D010406:Penicillins; D019818:Clavulanic Acid; D013982:Ticarcillin; D010878:Piperacillin